Investing.comDoubao · 实盘不做把握 7/10不做原因:已被定价
北京时间·🕒 发布 20:12:37·⟳ 抓取 20:12:59 +22s·⚡ 决策 10-20 23:48:50 +3h35m·6.9 天前
Actinium公布ATNM-400前列腺癌I期首批3例安全性数据：最低剂量无DLT并升至1.5剂量组
这是I期最低剂量3例患者的安全性更新（无DLT在最低剂量属预期之内），无任何疗效数据；公司10月15日已预先公告该EANM报告并预告初步发现，股价10月15-19日连续放量上涨（+8.8%、+6.6%、+16.8%，5日+24.5%），今日盘中已+9.85%反映数据，剩余edge不足以承担微盘股I期事件的高波动风险。
📄 原文Investing.com↗ 原文
Actinium advances HER3-targeted prostate cancer therapy to next dose
Netflix to report; OpenAI’s reported fundraising plans - what’s moving markets NEW YORK - Actinium Pharmaceuticals Inc.…
不做 Actinium Pharmaceuticals（ATNM.US）
弱催化（I期最低剂量3例安全性、无疗效信号）+强price-in（10月15日预告后三日放量累涨约35%，今日盘中再涨约10%），微盘股事件后回撤风险大于剩余edge，不追多；亦无做空红线级利空，不出空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ATNM-400首批3例I期安全性数据方向正面但仅为最低剂量、无疗效读出；报告日和初步结论10月15日已被公司预告，股价过去三个交易日放量累涨约35%、今日再涨约10%，催化已被提前定价，不追。
消息传播链
- 公司10月15日公告将在EANM 2026做ATNM-400首个人体I期口头报告，并预告初步发现，市场提前获知读出窗口市场反应:10月15日起股价连续放量上涨：+8.8%、+6.6%、10月19日+16.8%
- 周日大会报告首批3例1.0 µCi/kg无DLT、推进至1.5 µCi/kg；10月20日公司IR/PRNewswire发布正式新闻稿
- AI辅助撰写的媒体转述，无新增事实；当日盘中ATNM上涨约9.85%至1.45美元，继续消化该数据
关键理由
- 仅有的正面逻辑是无DLT验证HER3靶向Ac-226疗法在人体的初步耐受性并允许剂量递增，但属I期早期安全性而非疗效里程碑
主要风险
- 更高剂量（1.5-3.0 µCi/kg）可能出现DLT，且微盘股（市值约4560万美元）I期数据事件波动极大、回撤风险高
- 股价已在大会前连续放量抢跑，若后续无疗效催化剂，事件后存在sell-the-news回落风险
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-20 · 影响 weakens
新闻稿仅含3例安全性与PET摄取，无RECIST/PSA缓解数据；3+3设计尚处最低剂量，无DLT预期性强，不能外推疗效
检索:ATNM-400 phase 1 efficacy response DLT safety criticism - 做多前查反向 · 来源 web · 影响 weakens
公司为尚未盈利的微盘biotech（市值约4560万美元、PE为负），I期阶段长期依赖股权融资，存在稀释风险，未发现本次事件对应的近期融资公告
检索:Actinium Pharmaceuticals cash runway dilution offering 2026
先例如何影响了这次决策
对本次决策的影响:不依赖先例定tp/sl；结合自身抢跑+仅安全性无疗效的弱催化，直接以price-in为由AVOID
方向:未构建可用先例面板
涨幅量级:无法用先例校准幅度
形态:本标的自身轨迹已显示明确的事件前抢跑（10月15-19日连续放量上涨约35%），与典型会议数据sell-the-news风险形态一致
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 17 ms
{"result": "search_processed_events:agent query=`actinium pharmaceuticals atnm-400 phase 1 prostate cancer dose escalation | atnm-400 1.0 μci/kg first cohort no dose-limiting toxicities | barecetamab actinium-225 her3 eanm vienna`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - fetch_decision_experience 成功 stock_tools_inprocess · 3 ms
{ - stock_quote 成功 stock_tools HTTP · 3,129 ms
{ - web_search 成功 doubao_search · 1,994 ms
豆包搜索结果（原始查询:Actinium Pharmaceuticals ATNM-400 barecetamab Actinium-225 prostate cancer EANM phase 1 results press release；API SearchType:web）
原文全文
展开原文 · 2,115 字
Netflix to report; OpenAI’s reported fundraising plans - what’s moving markets
NEW YORK - Actinium Pharmaceuticals Inc. (NYSE American:ATNM) reported initial results from a Phase 1 study of ATNM-400, an experimental radiotherapy for metastatic castration-resistant prostate cancer, according to a press release statement issued today.
The first three patients completed treatment at the initial dose level of 1.0 µCi/kg with no dose-limiting toxicities, xerostomia or Grade 3/4 hematologic adverse events observed. The study has advanced to the second dose level of 1.5 µCi/kg.
ATNM-400 combines the monoclonal antibody barecetamab with Actinium-225, targeting HER3 rather than PSMA. The findings were presented Sunday at the 39th Annual Congress of the European Association of Nuclear Medicine in Vienna, Austria.
All three patients in the initial cohort had received prior androgen receptor pathway inhibitor therapy, two had received chemotherapy, and one had received Lutetium-177-PSMA therapy. At the time of presentation, all three had received at least two cycles of ATNM-400, with two patients receiving three cycles.
PET imaging using Zirconium-89-labeled barecetamab showed tumor uptake retained through Day 7. No elevations in liver enzymes or creatinine, injection-site reactions, or infusion-related reactions were observed during the reported follow-up period.
The ongoing study uses a 3+3 dose-escalation design in patients with progressive metastatic castration-resistant prostate cancer who have received at least one androgen receptor pathway inhibitor and at least one taxane regimen. Planned dose levels are 1.0, 1.5, 2.25 and 3.0 µCi/kg.
ATNM-400 is administered intravenously every six weeks for up to four cycles. The study evaluates safety, dosimetry and pharmacokinetics, with dose expansion intended to establish the recommended Phase 2 dose.
Actinium stated that preclinical studies showed antitumor activity across PSMA-high, PSMA-low and PSMA-negative prostate cancer models.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW YORK - Actinium Pharmaceuticals Inc. (NYSE American:ATNM) reported initial results from a Phase 1 study of ATNM-400, an experimental radiotherapy for metastatic castration-resistant prostate cancer, according to a press release statement issued today.
The first three patients completed treatment at the initial dose level of 1.0 µCi/kg with no dose-limiting toxicities, xerostomia or Grade 3/4 hematologic adverse events observed. The study has advanced to the second dose level of 1.5 µCi/kg.
ATNM-400 combines the monoclonal antibody barecetamab with Actinium-225, targeting HER3 rather than PSMA. The findings were presented Sunday at the 39th Annual Congress of the European Association of Nuclear Medicine in Vienna, Austria.
All three patients in the initial cohort had received prior androgen receptor pathway inhibitor therapy, two had received chemotherapy, and one had received Lutetium-177-PSMA therapy. At the time of presentation, all three had received at least two cycles of ATNM-400, with two patients receiving three cycles.
PET imaging using Zirconium-89-labeled barecetamab showed tumor uptake retained through Day 7. No elevations in liver enzymes or creatinine, injection-site reactions, or infusion-related reactions were observed during the reported follow-up period.
The ongoing study uses a 3+3 dose-escalation design in patients with progressive metastatic castration-resistant prostate cancer who have received at least one androgen receptor pathway inhibitor and at least one taxane regimen. Planned dose levels are 1.0, 1.5, 2.25 and 3.0 µCi/kg.
ATNM-400 is administered intravenously every six weeks for up to four cycles. The study evaluates safety, dosimetry and pharmacokinetics, with dose expansion intended to establish the recommended Phase 2 dose.
Actinium stated that preclinical studies showed antitumor activity across PSMA-high, PSMA-low and PSMA-negative prostate cancer models.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
aada6a5a2d· 2026-10-20 23:48 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前